News
Emerging peer-reviewed research suggests that non-psychoactive cannabidiol (CBD) may do more than reduce inflammation—it may influence molecular pathways involved in intestinal fibrosis and gut health. Recent studies highlight CBD’s interaction with key signaling systems such as Nrf2 and TGF-β/SMAD, offering new insight into how cannabinoids may support gut resilience without intoxication. This science-forward review breaks down what the latest research actually shows.
Ehlers-Danlos Syndrome (EDS) is a debilitating connective tissue disorder with limited treatment options, but cannabinoids like CBG, CBN, and full-spectrum hemp extracts are emerging as powerful allies. CBG’s anti-inflammatory and neuroprotective properties help reduce joint pain, while CBN promotes deep sleep and muscle relaxation. Full-spectrum hemp enhances these benefits through the entourage effect, amplifying pain relief and reducing anxiety. Peer-reviewed studies highlight the therapeutic potential of these cannabinoids, offering hope to those struggling with chronic pain, dislocations, and insomnia. As real-life cases show, individuals with EDS are finding relief and improved quality of life through targeted cannabinoid therapy, making it a promising avenue for symptom management.
